Abstract
Purpose
Tumor cell resistance to platinum-based chemotherapeutic agents is one of the major hurdles to successful cancer treatment with these drugs, and is associated with alterations in tumor cell immune evasion and immunomodulatory properties. Immunocyte targeting is considered as a relevant approach to fight drug-resistant cancer. In this study, immunological hallmarks of cis-DDP-resistant Lewis lung carcinoma cells (LLC/R9) were investigated.
Methods
Immunological features of LLC/R9 cells cultured in vitro in normoxic and hypoxic conditions as well as of those that were grown in vivo were examined. The expression of immunologically relevant genes was evaluated by RT-PCR. Tumor cell susceptibility to the macrophage contact tumoricidal activity and NK-mediated cytolysis was investigated in MTT test. TNF-α-mediated tumor cell apoptosis as well as macrophage phagocytosis, oxidative metabolism, and CD206 expression after the treatment with conditioned media from normoxic and hypoxic tumor cells were studied by flow cytometry. Flow cytometry was also used to characterize dendritic cell maturity.
Results
When growing in vitro, LLC/R9 were characterized by slightly increased immunosuppressive cytokine gene expression. Transition to in vivo growth was associated with the enhancement of transcription of these genes in tumor cells. LLC/R9 cells had lowered sensitivity to contact-dependent macrophage-mediated cytotoxicity and to the TNFα-mediated apoptosis in vitro. Conditioned media from hypoxic LLC/R9 cells stimulated reactive oxygen species generation and CD206 expression in non-sensitized macrophages. Acquisition of drug resistance by LLC/R9 cells was associated with their increased sensitivity to NK-cell-mediated cytolysis. Meanwhile, the treatment of LLCR/9-bearing animals with generated ex vivo and loaded with LLC/R9 cell-lysate dendritic cells (DCs) resulted in profoundly enhanced tumor metastasizing.
Conclusion
Decreased sensitivity to macrophage cytolysis, polarizing effect on DCs maturation along with increased susceptibility to NK-cell cytotoxic action promote extensive local growth of chemoresistant LLC/R9 tumors in vivo, but hamper their metastasizing.
Similar content being viewed by others
References
Hamilton G, Rath B (2014) A short update on cancer chemoresistance. Wien Med Wochenschr 164(21–22):456–460. https://doi.org/10.1007/s10354-014-0311-z
Gómez-Miragaya J, Palafox M, Paré L, Yoldi G, Ferrer I, Vila S, Galván P, Pellegrini P, Pérez-Montoyo H, Igea A, Muñoz P, Esteller M, Nebreda AR, Urruticoechea A, Morilla I, Pernas S, Climent F, Soler-Monso MT, Petit A, Serra V, Prat A, González-Suárez E (2017) Resistance to taxanes in triple-negative breast cancer associates with the dynamics of a CD49f+ tumor-initiating population. Stem Cell Rep 8(5):1392–1407. https://doi.org/10.1016/j.stemcr.2017.03.026
Bilen MA, Hess KR, Campbell MT, Wang J, Broaddus RR, Karam JA, Ward JF, Wood CG, Choi SL, Rao P, Zhang M, Naing A, General R, Cauley DH, Lin SH, Logothetis CJ, Pisters LL, Tu SM (2016) Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget 7(52):86280–86289. https://doi.org/10.18632/oncotarget.13380
Senthebane DA, Rowe A, Thomford NE, Shipanga H, Munro D, Mazeedi MAMA., Almazyadi HAM, Kallmeyer K, Dandara C, Pepper MS, Parker MI, Dzobo K (2017) The role of tumor microenvironment in chemoresistance: to survive, keep your enemies closer. Int J Mol Sci 18(7):E1586. https://doi.org/10.3390/ijms18071586
Hölzel M, Bovier A, Tüting T (2013) Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer 13(5):365–376. https://doi.org/10.1038/nrc3498
Fouad YA, Aanei C (2017) Revisiting the hallmarks of cancer. Am J Cancer Res 7(5):1016–1036
Chacon JA, Schutsky K, Powell DJ (2016) The impact of chemotherapy, radiation and epigenetic modifiers in cancer cell expression of immune inhibitory and stimulatory molecules and anti-tumor efficacy. Vaccines (Basel) 4(4)E43. https://doi.org/10.3390/vaccines4040043
Triba MN, Starzec A, Bouchemal N, Guenin E, Perret GY, Le Moyec L (2010) Metabolomic profiling with NMR discriminates between biphosphonate and doxorubicin effects on B16 melanoma cells. NMR Biomed 23(9):1009–1016. https://doi.org/10.1002/nbm.1516
Zub KA, Sousa MM, Sarno A, Sharma A, Demirovic A, Rao S, Young C, Aas PA, Ericsson I, Sundan A, Jensen ON, Slupphaug G (2015) Modulation of cell metabolic pathways and oxidative stress signaling contribute to acquired melphalan resistance in multiple myeloma cells. PLoS One 10(3):e0119857. https://doi.org/10.1371/journal.pone.0119857
Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22(47):7265–7279
Gottesman MM, Lavi O, Hall MD, Gillet JP (2016) Towards a better understanding of the complexity of cancer drug resistance. Annu Rev Pharmacol Toxicol 56:85–102. https://doi.org/10.1146/annurev-pharmtox-010715-103111
Shen DW, Pouliot LM, Hall MD, Gottesman MM (2012) Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev 64(3):706–721. https://doi.org/10.1124/pr.111.005637
Wangpaichitr M, Kandemir H, Li YY, Wu C, Nguyen D, Feun LG, Kuo MT, Savaraj N (2017) Relationship of metabolic alterations and PD-L1 expression in cisplatin resistant lung cancer. Cell Dev Biol 6(2):183. https://doi.org/10.4172/2168-9296.1000183
Barr MP, Gray SG, Hoffmann AC, Hilger RA, Thomale J, O’Flaherty JD, Fennell DA, Richard D, O’Leary JJ, O’Byrne KJ (2013) Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One 8(1):e54193. https://doi.org/10.1371/journal.pone.0054193
Zhang Q, Cai DJ, Li B (2015) Ovarian cancer stem-like cells elicit the polarization of M2 macrophages. Mol Med Rep 11(6):4685–4693. https://doi.org/10.3892/mmr.2015.3323
Raggi C, Mousa HS, Correnti M, Sica A, Invernizzi P (2016) Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies. Oncogene 35(6):671–682. https://doi.org/10.1038/onc.2015.132
Levina V, Su Y, Nolen B, Liu X, Gordin Y, Lee M, Lokshin A, Gorelik E (2008) Chemotherapeutic drugs and human tumor cells cytokine network. Int J Cancer 123(9):2031–2040. https://doi.org/10.1002/ijc.23732
Zhang F, Duan S, Tsai Y, Keng PC, Chen Y, Lee SO, Chen Y (2016) Cisplatin treatment increases stemness through upregulation of hypoxia-inducible factors by interleukin-6 in non-small cell lung cancer. Cancer Sci 107(6):746–754. https://doi.org/10.1111/cas.12937
Castells M, Thibault B, Delord JP, Couderc B (2012) Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death. Int J Mol Sci 13(8):9545–9571. https://doi.org/10.3390/ijms13089545
Wang W, Kryczek I, Dostál L, Lin H, Tan L, Zhao L, Lu F, Wei S, Maj T, Peng D, He G, Vatan L, Szeliga W, Kuick R, Kotarski J, Tarkowski R, Dou Y, Rattan R, Munkarah A, Liu JR, Zou W (2016) Effector T cells abrogate stroma-mediated chemoresistance in ovarian cancer. Cell 165(5):1092–1105. https://doi.org/10.1016/j.cell.2016.04.009
Solyanik GI, Pyaskovskaya ON, Garmanchouk LV (2003) Cisplatin-resistant Lewis lung carcinoma cells possess increased level of VEGF secretion. Exp Oncol 25(4):260–265
Pyaskovskaya ON, Dasyukevich OI, Kolesnik DL, Garmanchouk LV, Solyanik GI (2007) Changes in VEGF level and tumor growth characteristics during Lewis lung carcinoma progression towards cis-DDP resistance. Exp Oncol 29:197–202
Solyanik GI, Fedorchuk AG, Pyaskovskaya ON, Dasyukevich OI, Khranovskaya NN, Aksenov GN, Sobetsky VV (2004) Anticancer activity of aconitine-containing herbal extract BC1. Exp Oncol 26:307–311
Kolesnik DL, Pyaskovskaya ON, Dasyukevich OI, Solyanik GI (2010) Significant antimetastatic efficacy of metronomic low-dose oral cyclophosphamide against highly angiogenic variant of Lewis lung carcinoma. Tumor Host Novel Asp Old Prob Int Conf (Kiev, 21–24 Sept., 2010) Exp Oncol 32(Suppl.):94
Fedorchuk OG, Pyaskovskaya OM, Skivka LM, Gorbik GV, Trompak OO, Solyanik GI (2012) Paraneoplastic syndrome in mice bearing high-angiogenic variant of Lewis lung carcinoma: Relations with tumor derived VEGF. Cytokine 57(1):81–88. https://doi.org/10.1016/j.cyto.2011.10.022
Engblom C, Pfirschke C, Pittet MJ (2016) The role of myeloid cells in cancer therapies. Nat Rev Cancer 16(7):447–462. https://doi.org/10.1038/nrc.2016.54
Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE (2008) Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 3:e3077. https://doi.org/10.1371/journal.pone.0003077
Skivka LM, Fedorchuk OG, Rudyk MP, Pozur VV, Khranovska NM, Grom MY, Nowicky JW (2013) Antineoplastic drug NSC631570 modulates functions of hypoxic macrophages. Tsitol Genet 47(5):70–82
Sánchez A, Factor VM, Espinoza LA, Schroeder IS, Thorgeirsson SS (2004) In vitro differentiation of rat liver derived stem cells results in sensitization to TNFalpha-mediated apoptosis. Hepatology 40(3):590–599. https://doi.org/10.1002/hep.20363
Prylutska SV, Skivka LM, Didenko GV, Prylutskyy YI, Evstigneev MP, Potebnya GP, Panchuk RR, Stoika RS, Ritter U, Scharff P (2015) Complex of C60 fullerene with doxorubicin as a promising agent in antitumor therapy. Nanoscale Res Lett 10(1):499. https://doi.org/10.1186/s11671-015-1206-7
Robinson SP, Stagg AJ (2001) Dendritic cell protocol, Humana Press Inc, New York, p 270
Maldonado-López R, De Smedt T, Pajak B, Heirman C, Thielemans K, Leo O, Urbain J, Maliszewski CR, Moser M (1999) Role of CD8alpha + and CD8alpha- dendritic cells in the induction of primary immune responses in vivo. J Leukoc Biol 66(2):242–246
Yoo PS, Mulkeen AL, Cha CH (2006) Post-transcriptional regulation of vascular endothelial growth factor: implications for tumor angiogenesis. World J Gastroenterol 12(31):4937–4942
Arcondéguy T, Lacazette E, Millevoi S, Prats H, Touriol C (2013) VEGF-A mRNA processing, stability and translation: a paradigm for intricate regulation of gene expression at the post-transcriptional level. Nucleic Acids Res 41(17):7997–8010. https://doi.org/10.1093/nar/gkt539
Segura E, Nicco C, Lombard B, Véron P, Raposo G, Batteux F, Amigorena S, Théry C (2005) ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming. Blood 106(1):216–223. https://doi.org/10.1182/blood-2005-01-022
Kodaira Y, Nair SK, Wrenshall LE, Gilboa E, Platt JL (2000) Phenotypic and functional maturation of dendritic cells mediated by heparan sulfate. J Immunol 165(3):1599–1604
Wicki A, Mandalà M, Massi D, Taverna D, Tang H, Hemmings BA, Xue G (2016) Acquired resistance to clinical cancer therapy: a twist in physiological signaling. Physiol Rev 96(3):805–829. https://doi.org/10.1152/physrev.00024.2015
De Palma M, Lewis CE (2011) Cancer: macrophages limit chemotherapy. Nature 472(7343):303–304. https://doi.org/10.1038/472303a
Buck MD, Sowell RT, Kaech SM, Pearce EL (2017) Metabolic instruction of immunity. Cell 169(4):570–586. https://doi.org/10.1016/j.cell.2017.04.004
Kareva I, Hahnfeldt P (2013) The emerging “hallmarks” of metabolic reprogramming and immune evasion: distinct or linked? Cancer Res 73(9):2737–2742. https://doi.org/10.1158/0008-5472
Jinushi M (2012) Chronic activation of DNA damage signals causes tumor immune evasion in the chemoresistant niche. Oncoimmunology 1(3):400–402. https://doi.org/10.4161/onci.19123
Mocellin S, Panelli M, Wang E, Rossi CR, Pilati P, Nitti D, Lise M, Marincola FM (2004) IL-10 stimulatory effects on human NK cells explored by gene profile analysis. Genes Immun 5(8):621–630
Terme M, Colussi O, Marcheteau E, Tanchot C, Tartour E, Taieb J (2012) Modulation of immunity by antiangiogenic molecules in cancer. Clin Dev Immunol. 2012:492920. https://doi.org/10.1155/2012/492920
Voron T, Marcheteau E, Pernot S, Colussi O, Tartour E, Taieb J, Terme M (2014) Control of the immune response by pro-angiogenic factors. Front Oncol 4:70. https://doi.org/10.3389/fonc.2014.00070
Nissinen L, Kähäri VM (2014) Matrix metalloproteinases in inflammation. Biochim Biophys Acta 1840(8):2571–2580. https://doi.org/10.1016/j.bbagen.2014.03.007
Chimal-Ramírez GK, Espinoza-Sánchez NA, Fuentes-Pananá EM (2015) A role for the inflammatory mediators Cox-2 and metalloproteinases in cancer stemness. Anticancer Agents Med Chem 15(7):837–855
Anastasov A, Vlaykova T (2011) Matrix metalloproteinases in tumor biology—a special attention on their role in HNSCC. Trakia J Sci 9(3):74–81
Novitskiy SV, Forrester E, Pickup MW, Gorska AE, Chytil A, Aakre M, Polosukhina D, Owens P, Yusupova DR, Zhao Z, Ye F, Shyr Y, Moses HL (2014) Attenuated transforming growth factor beta signaling promotes metastasis in a model of HER2 mammary carcinogenesis. Breast Cancer Res 16(5):425. https://doi.org/10.1186/s13058-014-0425-7
Huang S, Peng L, Tang Y, Zhang L, Guo W, Zou X, Peng X (2013) Hypoxia of PC-3 prostate cancer cells enhances migration and vasculogenesis in vitro of bone marrow-derived endothelial progenitor cells by secretion of cytokines. Oncol Rep 29(6):2369–2377. https://doi.org/10.3892/or.2013.2363
Zhang Y, Choksi S, Chen K, Pobezinskaya Y, Linnoila I, Liu ZG (2013) ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumor-associated macrophages. Cell Res 23(7):898–914. https://doi.org/10.1038/cr.2013.75
Osinsky S, Zavelevich M, Vaupel P (2009) Tumor hypoxia and malignant progression. Exp Oncol 31(2):80–86
Jain M, Rivera S, Monclus EA, Synenki L, Zirk A, Eisenbart J, Feghali-Bostwick C, Mutlu GM, Budinger GR, Chandel NS (2013) Mitochondrial reactive oxygen species regulate transforming growth factor-β signaling. J Biol Chem 288(2):770–777. https://doi.org/10.1074/jbc.M112.431973
Murray LA, Chen Q, Kramer MS, Hesson DP, Argentieri RL, Peng X, Gulati M, Homer RJ, Russell T, van Rooijen N, Elias JA, Hogaboam CM, Herzog EL (2011) TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P. Int J Biochem Cell Biol 43(1):154–162. https://doi.org/10.1016/j.biocel.2010.10.013
Arsenijevic M, Milovanovic M, Jovanovic S, Arsenijevic N, Markovic BS, Gazdic M, Volarevic V (2017) In vitro and in vivo anti-tumor effects of selected platinum(IV) and dinuclear platinum(II) complexes against lung cancer cells. J Biol Inorg Chem 22(6):807–817. https://doi.org/10.1007/s00775-017-1459-y
Petersson M, Charo J, Salazar-Onfray F, Noffz G, Mohaupt M, Qin Z, Klein G, Blankenstein T, Kiessling R (1996) Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1. J Immunol 161(5):2099–2105
Ayalon O, Hughes EA, Cresswell P, Lee J, O’Donnell L, Pardi R, Bender JR (1998) Induction of transporter associated with antigen processing by interferon gamma confers endothelial cell cytoprotection against natural killer-mediated lysis. Proc Natl Acad Sci USA 95(5):2435–2440
Xu X, Rao GS, Groh V, Spies T, Gattuso P, Kaufman HL, Plate J, Prinz RA (2011) Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression. BMC Cancer 11:194. https://doi.org/10.1186/1471-2407-11-194
Anguille S, Van Acker HH, Van den Bergh J, Willemen Y, Goossens H, Van Tendeloo VF, Smits EL, Berneman ZN, Lion E (2015) Interleukin-15 dendritic cells harness NK cell cytotoxic effector function in a contact- and IL-15-dependent manner. PLoS One 10(5):e0123340. https://doi.org/10.1371/journal.pone.0123340
Ferlazzo G, Morandi B (2014) Cross-talks between natural killer cells and distinct subsets of dendritic cells. Front Immunol 5:159. https://doi.org/10.3389/fimmu.2014.00159
Yewdall AW, Drutman SB, Jinwala F, Bahjat KS, Bhardwaj N (2010) CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells. PLoS One 5(6):e11144. https://doi.org/10.1371/journal.pone.0011144
Funding
No funding was received for this work.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors state that they have no conflict of interest.
Ethical approval
Animal protocol was reviewed and approved by the IEPOR NASU and Taras Shevchenko National University animal welfare committee according to the Animal Welfare Act guidelines. Study was conducted in compliance with the standards of the Convention on Bioethics of the Council of Europe ‘Europe Convention for the Protection of Vertebrate Animals used for experimental and other scientific purposes’ (1997), the general ethical principles of animal experiments, approved by the First National Congress on Bioethics in Ukraine (September 2001) and national law (LAW OF UKRAINE no. 3447-IV) issued by the Cabinet of Ministers of Ukraine (2006).
Rights and permissions
About this article
Cite this article
Fedorchuk, O., Susak, Y., Rudyk, M. et al. Immunological hallmarks of cis-DDP-resistant Lewis lung carcinoma cells. Cancer Chemother Pharmacol 81, 373–385 (2018). https://doi.org/10.1007/s00280-017-3503-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-017-3503-6